pipette
ENEnglish

More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab

T. P. Copeland, S. Abdel Hay, F. Piehl, K. Fink, K. A. McKay

Preprint

En palabras de los autores

Background: The Symbol Digit Modalities Test (SDMT) measures information processing speed, and repeated testing can increase scores through practice effects. However, how differences in testing frequency bear on comparisons between disease-modifying therapies (DMTs) in real-world cohorts has not been fully explored. Objective: To compare SDMT trajectories between natalizumab and rituximab users and quantify the association of the testing process with those trajectories. Methods: Using the Swedish MS Registry, we studied adults with relapsing-remitting MS initiating natalizumab or rituximab (2010-2024) with >=2 on-treatment SDMT assessments. Mixed-effects models with restricted cubic spline time were sequentially adjusted; log cumulative test number was the practice-effect adjustment. Results: Among 2,458 individuals, natalizumab initiators were tested twice as often as rituximab initiators (1.6 vs. 0.8 tests/year). The predicted natalizumab-minus-rituximab SDMT difference at 3 years was 7.0 points (95% CI 5.7-8.3) unadjusted and 1.6 (0.7-2.6) after full adjustment including cumulative test number; at 1 year it fell from 4.4 (3.3-5.4) to -0.3 (-1.2 to 0.6). Conclusion: Adjustment for cumulative test number substantially attenuated the SDMT difference between natalizumab and rituximab, leaving a small residual difference of uncertain clinical importance and underscoring the need to account for testing frequency in real-world comparisons.

Resultado principalLimitación que admiten los autores

Apareció: sábado, 24 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.21.26366102